This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Pre-clinical Validation of Orthotopically-implanted Pulmonary Tumor by Imaging with 18F-Fluorothymidine-Positron Emission Tomography/Computed Tomography
- Prediction Model of Chemotherapy Response in Osteosarcoma by 18F-FDG PET and MRI
- Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine
- PET for Sarcomas Other Than Gastrointestinal Stromal Tumors
- PET Imaging of Osteosarcoma
- Rat Studies Comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as Proliferation Markers
- Clinical Applications of 18F-FDG in Oncology
- Relationship Between Retention Index in Dual-Phase 18F-FDG PET, and Hexokinase-II and Glucose Transporter-1 Expression in Pancreatic Cancer
- Glucose Metabolism of Breast Cancer Assessed by 18F-FDG PET: Histologic and Immunohistochemical Tissue Analysis
- Grading of Tumors and Tumorlike Lesions of Bone: Evaluation by FDG PET
- (F-18) Fluorodeoxyglucose Positron Emission Tomography as a Predictor of Pathologic Grade and Other Prognostic Variables in Bone and Soft Tissue Sarcoma
- Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1